MTST (MetaStat) EBITDA Margin %: 0.00% (As of Feb. 2018)


What is MetaStat EBITDA Margin %?

MetaStat MTST EBITDA Margin % is 0.00% as of Feb. 2018.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MetaStat's EBITDA for the three months ended in Feb. 2018 was $-0.92 Mil. MetaStat's Revenue for the three months ended in Feb. 2018 was $0.00 Mil. Therefore, MetaStat's EBITDA margin for the quarter that ended in Feb. 2018 was 0.00%.

MetaStat  (OTCPK:MTST) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

MetaStat EBITDA Margin % Related Terms

MetaStat EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for MetaStat's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat EBITDA Margin % Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -12,926.09

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -973.91 0.00 0.00 0.00

MTST vs OBMP, NSPX, ATRX: EBITDA Margin % Comparison

For the Biotechnology subindustry, MetaStat's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MetaStat EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MetaStat's EBITDA Margin % falls into.


MetaStat EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MetaStat's EBITDA Margin % for the fiscal year that ended in Feb. 2018 is calculated as

EBITDA Margin %=EBITDA (A: Feb. 2018 )/Revenue (A: Feb. 2018 )
=-2.973/0.023
=-12,926.09 %

MetaStat's EBITDA Margin % for the quarter that ended in Feb. 2018 is calculated as

EBITDA Margin %=EBITDA (Q: Feb. 2018 )/Revenue (Q: Feb. 2018 )
=-0.919/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
MetaStat (MTST) has a EBITDA Margin % of 0.00% as of Feb. 2018. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MetaStat and its competitors.
Is MetaStat's EBITDA Margin % too high?
MetaStat's current EBITDA Margin % is 0.00%.
How does MetaStat's EBITDA Margin % compare to OBMP and NSPX?
MetaStat's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MetaStat and its competitors. MetaStat's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MetaStat (MTST), the current EBITDA Margin % is 0.00% as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.